This summary was created by AI, based on 5 opinions in the last 12 months.
The experts unanimously agree that ROIV is a top pick due to the Swiss based biopharma company's impressive pipeline of projects, strong financials, and positive reports on important autoimmune drugs. The company's cash reserves are consistently growing, while debt is being retired. It has also received supportive results for a new product, setting it up for potential growth in the future. The recent approval of a $1.2 billion share buyback further adds to its attractiveness as an investment.
Roivant is a American stock, trading under the symbol ROIV-Q on the NASDAQ (ROIV). It is usually referred to as NASDAQ:ROIV or ROIV-Q
In the last year, there was no coverage of Roivant published on Stockchase.
Roivant was recommended as a Top Pick by on . Read the latest stock experts ratings for Roivant.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Roivant In the last year. It is a trending stock that is worth watching.
On 2025-01-14, Roivant (ROIV-Q) stock closed at a price of $10.94.
We again reiterate ROIV as a TOP PICK. The Swiss based biopharma company continues to develop its long pipeline of projects. It trades at 2x earnings, under 2x book and supports a robust 128% ROE. We like that cash reserves are growing, while debt is retired. We continue to recommend a stop-loss at $10.50, looking to achieve $16 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $16.25)